Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Invagen Pharmaceuticals Private Limited, was an unlisted private company incorporated on 17 November, 2004. It is classified as a private limited company and is located in , Telangana. It's authorized share capital was INR 1.00 cr and the total paid-up capital was INR 1.00 lac.
The current status of Invagen Pharmaceuticals Private Limited is - Strike Off.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
9.29%
7.69%
-68.97%
2.15%
6.23%
5.07%
5.57
-0.31
-8.37
-8.01
-0.76
0.01
No Reports Available
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(1)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Venkatanarasa Reddy Attunuri | 00023432 | 20 years |
| Director | Chandra Sekhar Tumuluru | 07212178 | 9 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| HETERO BIOTECH LIMITED |
Strike Off
|
5.0 L | 1 | Telangana |
| EXPICOR PHARMA PRIVATE LIMITED |
Strike Off
|
4.5 L | 1 | Telangana |
| AGRATA LAB PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
| HETERO DRUGS LIMITED |
Active
|
3.5 Cr | 1 | Telangana |
| HETERO LABS LIMITED |
Active
|
277.1 Cr | 1 | Telangana |
| STRIVO PHARMA PRIVATE LIMITED |
Active
|
6.0 L | 1 | Telangana |
| SVS DRUGS AND PHARMACEUTICALS PVT LTD |
Active
|
4.2 L | 1 | Telangana |
| YATNAM LAB LIMITED |
Active
|
10.0 L | 1 | Telangana |
| ASPHAR RESEARCH LABS PRIVATE LIMITED |
Active
|
10.0 L | 1 | Telangana |
| CLIWIS LAB PRIVATE LIMITED |
Active
|
4.0 L | 1 | Telangana |
| CIREX PHARMACEUTICALS PRIVATE LIMITED |
Active
|
4.2 Cr | 1 | Telangana |
| HONOUR INFRA ESTATES LIMITED |
Active
|
5.8 Cr | 1 | Telangana |
| VEER EAST REALTY INDIA PRIVATE LIMITED |
Active
|
13.8 Cr | 1 | Telangana |
| SELMAR LAB PRIVATE LIMITED |
Active
|
4.5 Cr | 1 | Telangana |
| SRI SAI ASHIRWAAD ENTERPRISES LIMITED |
Active
|
5.0 L | 1 | Telangana |
| SRI SHAKTI SWAROOPINI INDUSTRY PRIVATE LIMITED |
Amalgamated
|
1.0 L | 1 | Telangana |
| DYUMAT HOTELS LIMITED |
Active
|
5.0 L | 1 | Karnataka |
| SREE SAI LOK INDUSTRY PRIVATE LIMITED |
Amalgamated
|
1.0 L | 1 | Telangana |
| JITVAN LAND LIMITED |
Active
|
5.0 L | 1 | Karnataka |
| WALLET PHARMA PRIVATE LIMITED |
Active
|
98.0 Cr | 1 | Telangana |
| HOSTER LABS PRIVATE LIMITED |
Active
|
1.0 Cr | 1 | Telangana |
| HETERO MARBLES PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
| HETERO BIOPHARMA LIMITED |
Active
|
150.1 Cr | 1 | Telangana |
| HETERO LIFE SCIENCES PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
| EDIKAL INFRAVENTURES LLP |
Active
|
36.0 L | 1 | Telangana |
| SYGMOS LAB PRIVATE LIMITED |
Active
|
10.0 L | 1 | Andhra Pradesh |
| ANNORA PHARMA PRIVATE LIMITED |
Active
|
286.0 Cr | 1 | Telangana |
| VEER WEST REALTY INDIA PRIVATE LIMITED |
Active
|
15.4 Cr | 1 | Telangana |
| ASPIRO PHARMA LIMITED |
Active
|
254.1 Cr | 1 | Telangana |
The incorporation date of INVAGEN PHARMACEUTICALS PRIVATE LIMITED is 17 November, 2004
The authorized share capital of INVAGEN PHARMACEUTICALS PRIVATE LIMITED is INR ₹ 1.0 Cr.
The paid-up capital of INVAGEN PHARMACEUTICALS PRIVATE LIMITED is INR ₹ 1.0 L.
The registered address of INVAGEN PHARMACEUTICALS PRIVATE LIMITED is H.NO.8-3-166/7/1,THIRD FLOOR, HETERO HOUSE,ERRAGADDA HYDERABAD Hyderabad Telangana - 500018
The CIN number of INVAGEN PHARMACEUTICALS PRIVATE LIMITED is U24239TG2004PTC044633.
Expand
Delete
Collapse
See
details
It will take sometime. Please come back in 10
minutes
